NASDAQ:THOR - Synthorx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Synthorx Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $67.99 0.00 (0.00 %) (As of 01/23/2020) Add Compare Today's Range$67.99Now: $67.99▼$67.9950-Day Range$67.99MA: $68.32▼$70.8652-Week Range$11.05Now: $67.99▼$71.90VolumeN/AAverage Volume474,507 shsMarket Capitalization$2.20 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:THOR Previous Symbol CUSIP88517530 CIK350907 Webhttp://www.synthorx.com/ Phone858-750-4700Debt Debt-to-Equity RatioN/A Current Ratio18.87 Quick Ratio18.87Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.72 per share Price / Book10.12Profitability EPS (Most Recent Fiscal Year)($6.59) Net Income$-56,610,000.00 Net MarginsN/A Return on Equity-26.09% Return on Assets-24.62%Miscellaneous Employees39 Outstanding Shares32,338,000Market Cap$2.20 billion Next Earnings Date3/10/2020 (Estimated) OptionableNot Optionable Receive THOR News and Ratings via Email Sign-up to receive the latest news and ratings for THOR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:THOR Rates by TradingView Synthorx (NASDAQ:THOR) Frequently Asked Questions What is Synthorx's stock symbol? Synthorx trades on the NASDAQ under the ticker symbol "THOR." How were Synthorx's earnings last quarter? Synthorx Inc (NASDAQ:THOR) issued its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.12. View Synthorx's Earnings History. When is Synthorx's next earnings date? Synthorx is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Synthorx. What price target have analysts set for THOR? 5 analysts have issued twelve-month price objectives for Synthorx's stock. Their forecasts range from $30.00 to $68.00. On average, they anticipate Synthorx's share price to reach $53.80 in the next twelve months. This suggests that the stock has a possible downside of 20.9%. View Analyst Price Targets for Synthorx. What is the consensus analysts' recommendation for Synthorx? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthorx in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Synthorx. What are Wall Street analysts saying about Synthorx stock? Here are some recent quotes from research analysts about Synthorx stock: 1. According to Zacks Investment Research, "Synthorx Inc. is a biopharmaceutical company which focuses on cancer and autoimmune disorders. The company's product pipeline consists of THOR-707, IL-2 autoimmune synthorin, IL-10 synthorin and IL-15 synthorin which are in clinical stage. Synthorx Inc. is based in La Jolla, CA. " (1/10/2020) 2. HC Wainwright analysts commented, "Our 12-month, $30 price target on shares of Synthorx is based on a 12-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.5, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2029. We assign a 9% POS for THOR-707, which we anticipate could be developed in NSCLC, RCC, melanoma, and urothelial cancer. These indications together represent about 95% of our target with NSCLC being the biggest driver of valuation, elaborated upon subsequently." (5/1/2019) Has Synthorx been receiving favorable news coverage? Media coverage about THOR stock has been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Synthorx earned a media sentiment score of 3.1 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Synthorx. Who are some of Synthorx's key competitors? Some companies that are related to Synthorx include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD). What other stocks do shareholders of Synthorx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synthorx investors own include Pfizer (PFE), Editas Medicine (EDIT), EXACT Sciences (EXAS), NVIDIA (NVDA), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Penske Automotive Group (PAG), Exxon Mobil (XOM), Advanced Micro Devices (AMD) and Eiger Biopharmaceuticals (EIGR). Who are Synthorx's key executives? Synthorx's management team includes the folowing people: Dr. Laura K. Shawver, CEO, Pres & Director (Age 61)Dr. Floyd E. Romesberg, Scientific Founder & Director (Age 53)Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 56)Dr. Joseph Leveque, Chief Medical Officer (Age 58)Terry L. Button, VP & Director When did Synthorx IPO? (THOR) raised $100 million in an initial public offering on Friday, December 7th 2018. The company issued 9,100,000 shares at $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Synthorx's major shareholders? Synthorx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include ARP Americas LP (1.48%), Goldman Sachs Group Inc. (0.78%), State Street Corp (0.49%), Chicago Capital Management LLC (0.46%), Geode Capital Management LLC (0.43%) and Credit Suisse AG (0.40%). Company insiders that own Synthorx stock include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Institutional Ownership Trends for Synthorx. Which institutional investors are selling Synthorx stock? THOR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Russell Investments Group Ltd. and First Trust Advisors LP. View Insider Buying and Selling for Synthorx. Which institutional investors are buying Synthorx stock? THOR stock was bought by a variety of institutional investors in the last quarter, including ARP Americas LP, Chicago Capital Management LLC, Credit Suisse AG, Magnetar Financial LLC, Oxford Asset Management LLP, Glazer Capital LLC, Fort Baker Capital Management LP and Bank of America Corp DE. Company insiders that have bought Synthorx stock in the last two years include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Insider Buying and Selling for Synthorx. How do I buy shares of Synthorx? Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Synthorx's stock price today? One share of THOR stock can currently be purchased for approximately $67.99. How big of a company is Synthorx? Synthorx has a market capitalization of $2.20 billion. The medical instruments supplier earns $-56,610,000.00 in net income (profit) each year or ($6.59) on an earnings per share basis. Synthorx employs 39 workers across the globe.View Additional Information About Synthorx. What is Synthorx's official website? The official website for Synthorx is http://www.synthorx.com/. How can I contact Synthorx? Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected] MarketBeat Community Rating for Synthorx (NASDAQ THOR)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 408 (Vote Outperform)Underperform Votes: 444 (Vote Underperform)Total Votes: 852MarketBeat's community ratings are surveys of what our community members think about Synthorx and other stocks. Vote "Outperform" if you believe THOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2020 by MarketBeat.com StaffFeatured Article: What is the FTSE 100 index?
